Year in Review: Chronic Lymphocytic Leukemia Top news in 2024 included the first CAR-T approval for CLL, triplet regimens, and more Dec 10, 2024
Hydroxyurea Shows Some Benefits in Milder Sickle Cell Disease Treatment tied to fewer vaso-occlusive pain events, hospitalizations versus placebo Dec 09, 2024
Fixed-Duration Oral Doublet for Fit CLL Wins in Frontline Setting AMPLIFY trial paves the way for FDA approval of acalabrutinib plus venetoclax Dec 09, 2024
Treatment of Smoldering Myeloma Cuts Progression Rate in Half Daratumumab significantly improved PFS, OS, but identity of high-risk population remains elusive Dec 09, 2024
Novel BTK Inhibitor Succeeds in Heavily Pretreated Immune Thrombocytopenia Rilzabrutinib specifically designed to reduce platelet-targeting autoantibodies Dec 08, 2024
Dietary Intervention Shows Promise in Blood Cancers High-fiber diets tied to improved outcomes in stem-cell transplants, slowing myeloma precursors Dec 08, 2024
Dual Targeted CAR-T Yields 99% Response Rate in Pediatric ALL Cytokine release syndrome developed in all patients, including grade 3/4 events in nearly half Dec 07, 2024
New Standard for Newly Diagnosed Pediatric B-Cell Acute Lymphoblastic Leukemia Blinatumomab consolidation reduced risk of relapse by 61% versus chemotherapy alone Dec 07, 2024
Eltrombopag Improves Outcomes in Kids With Newly Diagnosed ITP Drug may potentially "transform" approach to upfront treatment, investigator says Dec 07, 2024
AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns News, features, and commentary about cancer-related issues Dec 05, 2024
Stem Cell Selection Unneeded for SSc Transplant Therapy? Small trial suggests a simpler path to defeat systemic sclerosis Dec 03, 2024
Year in Review: Multiple Myeloma A drug comeback, new FDA approvals, and a new standard for transplant-ineligible patients Dec 02, 2024
New CAR-T Drug Induces Durable Remissions in ALL, Published Data Show Results of FELIX study supported obecabtagene autoleucel's recent FDA approval Nov 27, 2024
FDA Investigating Blood Cancer Risk With Gene Therapy Skysona Agency is evaluating the need for further regulatory action Nov 27, 2024
Advances in TNBC; Mixed News in Lung Cancer Report; Pancreatic Cancer Overdiagnosis? News, features, and commentary about cancer-related issues Nov 22, 2024
FDA Approves First Menin Inhibitor for Acute Leukemia Complete responses in 21% of patients treated with single-agent revumenib Nov 15, 2024
Big Comeback for Myeloma Drug; DIY Cancer Therapy; Gut Clues to Bladder Cancer News, features, and commentary about cancer-related issues Nov 15, 2024
Electronic Symptom Screening in Kids With Cancer Boosts Quality of Care Improvements seen in pain, neuropathy, and cognitive function Nov 13, 2024
U.S. Nurse Found Dead; Harvey Weinstein's Cancer; Creepy Source of Ear Pain Health news and commentary gathered by MedPage Today staff Nov 11, 2024
New CAR T-Cell Therapy Approved for Leukemia Obecabtagene autoleucel has no requirement for a REMS program Nov 08, 2024
Asymptomatic or Minimally Symptomatic Myelofibrosis Momentum grows for earlier intervention, including pre-fibrotic disease Nov 04, 2024
Is It Really Cancer? More Concerns About Accelerated Approval; Metformin and Cancer News, features, and commentary about cancer-related issues Nov 01, 2024
Early Smoking Cessation After Cancer Diagnosis Tied to Better Survival Largest survival benefit observed in patients who entered a cessation program within 6 months Oct 31, 2024
Personalized Breast Cancer Treatment; Insights Into HPV in Men; Exercise and Cancer News, features, and commentary about cancer-related issues Oct 25, 2024
Nivolumab Regimen Achieves Durable PFS in Advanced Hodgkin's Lymphoma May become "treatment of choice" over brentuximab vedotin for all disease stages Oct 16, 2024
Study Details Perinatal Risks of Blood Cancers Diagnosed in Pregnancy Likelihood of severe maternal morbidity more than 20 times higher versus the general population Oct 11, 2024
Let's Talk Breast Density; Cancer, Movies, and Music; Treatment-Induced Aging? News, features, and commentary about cancer-related issues Oct 10, 2024
Gene Therapy for Rare Brain Disease Effective, but Comes With Blood Cancer Risk 10% of patients in trials leading to eli-cel's approval developed MDS or AML Oct 09, 2024
Good News for CAR-T Therapy; Liquid Biopsy Progress; Anti-Psychotic for Brain Cancer News, features, and commentary about cancer-related issues Oct 04, 2024
Cancer Treatment Ups CV Risk; Therapy's Next Big Thing; Nude Photos Settlement News, features, and commentary about cancer-related issues Sep 26, 2024
Sickle Cell Disease Drug Pulled From Global Markets Benefits of voxelotor (Oxbryta) no longer outweigh the risks, Pfizer says Sep 26, 2024
Gene Therapy for Hemophilia B Significantly Outperforms Factor IX Prophylaxis Fidanacogene elaparvovec reduces bleeding episodes by 71% after a single infusion Sep 25, 2024
Earlier Info on Financial Stress; Obesity and Second Cancers; Carcinogenic Condoms? News, features, and commentary about cancer-related issues Sep 19, 2024
Chemo-Free Triplet Yields 68% Response Rate in Richter Transformation Regimen tops best historical response rate with chemoimmunotherapy in this setting Sep 16, 2024
Cancer Diagnoses Still Lagging; Cancer and Family Health; New Type of Lung Cancer News, features, and commentary about cancer-related issues Sep 12, 2024
Second Malignancy Risk With CAR T-Cell Therapy on Par With Other Treatments Incidence almost identical to that with standard cancer treatment in randomized trials Sep 11, 2024
Study Supports Lactated Ringer Solution for Fluid Resuscitation in SCD For patients with vaso-occlusive episodes, lactated Ringer was better than normal saline Sep 09, 2024
Off-the-Shelf Drug Matches CAR-T Effects in Refractory Lupus Patient achieves remission with biologic agent currently used for myeloma Sep 04, 2024
The Higher the Disability Burden From Disease, the Higher the Suicide Risk Having a medical condition was tied to increased risk of suicide in a dose-response-like manner Sep 04, 2024
Infections the Main Cause of Nonrelapse Mortality After CAR-T for Blood Cancers Systematic review and meta-analysis finds CAR T-cell-specific toxicities only account for 11.5% Sep 04, 2024
